Inmed Pharmaceuticals Inc.
INMInmed Pharmaceuticals Inc. in brief
Inmed Pharmaceuticals Inc. is a listed company in the Biotechnology industry, based in Vancouver, Canada. Its market value was $9 M on 29 October 2026, which makes it the 26,125th largest listed company in the world and the 1,407th largest in Canada on this site. It employs about 6 people and Eric A. Adams is its chief executive. Its shares trade under the symbol INM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Inmed Pharmaceuticals Inc.
We are a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. Our research efforts target the treatment of diseases with high unmet medical needs. On March 4, 2026, the InMed Board ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica’s commercial operations business segment, which constitutes the only revenue-generating commercial operations of InMed. As of June 30, 2026, BayMedica had wound down all of its operating activities, and had two remaining employees who departed on July 31, 2026, as well as a commercial lease which will terminate at the end of August. Following the wind down of commercial operations, InMed’s remaining activities have consisted of preclinical development of its Product Candidates, including INM-901 for Alzheimer’s disease, INM-089 for dry Age-related Macular Degeneration or dry AMD, and INM-755 (cannabinol) cream. InMed does not currently intend to devote significant resources to advancing these Product Candidates, and any further development of them would require InMed to obtain additional financing, of which there can be no assurance.
From the company's annual report filed with the US SEC: read the report
Inmed Pharmaceuticals Inc. timeline
- 2018
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 💰Record revenue of $5 millionFY2025, the highest of the 5 years on record.
Events of Inmed Pharmaceuticals Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Canada: #1,403 (Jan 2022) · #1,627 (Jan 2024) · #59 (Mar 2026) · #830 (Aug 2026) · #1,495 (Oct 2026) · #1,407 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 8.2×
- Free cash flow yield
- -91.0%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -1163.0%
- Liabilities / assets
- 64.7%
- Revenue growth
- +7.4%
- R&D / revenue
- 57.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | — | — | — | $-13M | — |
| Jun 2025 | $5M | +7.4% | — | $-8M | -165.2% |
| Jun 2024 | $5M | +11.1% | — | $-8M | -167.0% |
| Jun 2023 | $4M | +279.8% | $-8M | $-8M | -192.0% |
| Jun 2022 | $1M | -42.6% | $-19M | $-19M | -1706.4% |
| Jun 2021 | $2M | — | $-10M | $-10M | -536.8% |
| Jun 2020 | — | — | — | $-9M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2026 | $-9M | — | — | $-3.12 | — |
| Jun 2025 | $-8M | $0M | $-8M | $-8.36 | — |
| Jun 2024 | $-7M | $0M | $-7M | $-20.14 | — |
| Jun 2023 | $-7M | $0M | $-7M | $-3.25 | — |
| Jun 2022 | $-16M | $0M | $-16M | $-33.17 | — |
| Jun 2021 | $-10M | $0M | $-10M | $-37.96 | — |
| Jun 2020 | $-7M | $0M | $-7M | $-1.71 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 20268-KCurrent reportMaterial agreement · Acquisition or disposal completed · Results of operations · Unregistered share sale · Change in control · Directors or officers changed · Bylaws amended
- Nov 9, 20268-KCurrent reportRegulation FD disclosure
- Nov 5, 20268-KCurrent reportRegulation FD disclosure
- Nov 5, 20268-KCurrent reportBylaws amended · Shareholder vote · Other events
- Nov 3, 20268-KCurrent reportRegulation FD disclosure
- Nov 3, 202610-QQuarterly report · period to Sep 2026
- Sep 18, 20268-KCurrent reportListing notice · Other events
- Sep 9, 202610-KAnnual report · period to Jun 2026
- Jul 22, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jul 10, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Jun 10, 20268-KCurrent reportOther events
- May 19, 20268-KCurrent reportMaterial agreement · Change in control · Directors or officers changed · Regulation FD disclosure
Official filings of Inmed Pharmaceuticals Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- —
- Net income
- $-13 M
For year ending June-2026 · source: SEC filing
Balance sheet
- Total assets
- $3 M
- Total liabilities
- $2 M
- Total equity
- $1 M
As of June-2026
Top 17 institutional investors in Inmed Pharmaceuticals Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Eventide Asset Management, LLC | 4,354,499 | New | 79.26% | $6 M | Nov 13, 2026 |
| 2 | Seven Fleet Capital Management LP | 1,069,519 | New | 19.47% | $1 M | Nov 16, 2026 |
| 3 | Vivo Capital, LLC | 824,874 | +26,497 (+3.32%) | 15.01% | $1 M | Nov 13, 2026 |
| 4 | Ikarian Capital, LLC | 137,634 | -107,391 (-43.83%) | 2.51% | $0 M | Nov 16, 2026 |
| 5 | Venrock Adviser, LLC | 133,378 | +100,693 (+308.07%) | 2.43% | $0 M | Nov 16, 2026 |
| 6 | Jane Street Group, LLC | 52,947 | +9,869 (+22.91%) | 0.96% | $0 M | Nov 12, 2026 |
| 7 | Citadel Advisors LLC | 42,972 | +16,888 (+64.74%) | 0.78% | $0 M | Nov 16, 2026 |
| 8 | Boothbay Fund Management, LLC | 39,915 | -34,329 (-46.24%) | 0.73% | $0 M | Nov 16, 2026 |
| 9 | Seven Grand Managers, LLC | 25,000 | 0 (0.00%) | 0.46% | $0 M | Nov 16, 2026 |
| 10 | XTX Topco Ltd | 19,047 | New | 0.35% | $0 M | Nov 16, 2026 |
| 11 | Crestwood Advisors Group, LLC | 14,900 | 0 (0.00%) | 0.27% | $0 M | Oct 27, 2026 |
| 12 | Two Sigma Investments, LP | 11,906 | New | 0.22% | $0 M | Nov 16, 2026 |
| 13 | Private Wealth Management Group, LLC | 5,000 | 0 (0.00%) | 0.09% | $0 M | Oct 19, 2026 |
| 14 | UBS Group AG | 3,194 | New | 0.06% | $0 M | Nov 10, 2026 |
| 15 | SBI Securities Co., Ltd. | 300 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 16 | Banque Cantonale Vaudoise | 6 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 17 | Federation des caisses Desjardins du Quebec | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding Inmed Pharmaceuticals Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 6,495 | $0 M | — | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Inmed Pharmaceuticals Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +2,640 | $13.10 | $35 K | 98,297 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +4 | $1.320 | $5 | 956,584 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +1,086 | $1.320 | $1 K | 956,580 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +1 | $1.320 | $1 | 955,494 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +984 | $1.322 | $1 K | 955,493 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +8,021 | $1.330 | $11 K | 954,509 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +564 | $1.330 | $750 | 946,488 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +2,256 | $1.328 | $3 K | 945,924 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Inmed Pharmaceuticals Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-11-11 14:32 UTC, code LUDP, resumed 14:37 UTC
- 2026-11-09 19:34 UTC, code LUDP, resumed 19:39 UTC
- 2026-11-09 19:18 UTC, code LUDP, resumed 19:23 UTC
- 2026-11-09 18:18 UTC, code LUDP, resumed 18:23 UTC
- 2026-11-09 18:12 UTC, code LUDP, resumed 18:17 UTC
Fails to deliver
- : 815 shares at $1.62
- : 12,292 shares at $1.59
- : 1,626 shares at $1.44
- : 3,470 shares at $1.36
- : 738 shares at $1.33
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Inmed Pharmaceuticals Inc. scorecard#
Passes 1 of the 12 checks that could be worked out. Fiscal year 2026; market cap of Oct 29, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median8.2×Price to book 8.2× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-91.0%Free cash flow is -91.0% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-3.12 vs -8.36Diluted EPS -3.12 in fiscal 2026 against -8.36 the year before (report's currency).
- ✗Net income higher than five years earlier-$13 M-$13 M in fiscal 2026 against -$10 M in 2021.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2026.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-173.1%-173.1% in fiscal 2026.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.37 at the end of fiscal 2026.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year326.6%Diluted shares up 326.6% in fiscal 2026.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Inmed Pharmaceuticals Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jun 30, 2026 | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | 4.9+7.5%100% | 4.6+11.2%100% | 4.1+280%100% | 1.1−42.8%100% | 1.9—100% | — | |
| Cost of revenue | — | 3.2−7.5%65.5% | 3.5+28.0%76.1% | 2.7r2.4+401%66.1% | 0.5—50.1% | — | — | |
| Gross profit | — | 1.7+55.0%34.5% | 1.1−21.5%23.9% | 1.4+158%33.9% | 0.5—49.9% | — | — | |
| Research and development | 3.0+7.3%— | 2.8r2.9−12.3%57.1% | 3.2r3.8−13.8%70.0% | 3.7−48.8%90.2% | 7.3+36.4%668% | 5.3−8.1%280% | 5.8—— | |
| General and administrative | 6.7+23.0%— | 5.4r6.6−6.6%110% | 5.8r5.3−0.8%126% | 5.8−14.8%141% | 6.9+53.3%630% | 4.5+38.8%235% | 3.2—— | |
| Operating expenses | 12+37.0%— | 8.5r9.7−8.8%171% | 9.3−5.4%202% | 9.8r9.8−44.8%238% | 18+79.2%1635% | 9.9+8.6%522% | 9.2—— | |
| Operating income | — | — | — | −7.9—−192% | −19—−1707% | −10—−536% | — | |
| Interest and finance income | 0.2+57.2%— | 0.2−70.5%3.2% | 0.5+7.2%11.5% | 0.5+412%11.9% | 0.1+500%8.8% | 0.0−87.6%0.8% | 0.1—— | |
| Net interest income | — | — | — | — | — | −0.4—−18.9% | — | |
| Other non-operating income (expense) | — | — | 0.5+7.2%11.5% | 0.5r0.4—11.9% | −1.3—−123% | −0.4—−18.9% | — | |
| Income before tax | −11—— | −8.7r−8.2—−176% | −7.7—−167% | −7.9—−192% | −19—−1707% | — | — | |
| Income tax | — | — | 0.0−45.8%0.2% | 0.0—0.3% | — | — | — | |
| Income from continuing operations | −11—— | −8.7—−176% | — | — | — | — | — | |
| Income from discontinued operations | −1.2−325%— | 0.5—10.7% | — | — | — | — | — | |
| Net income including minority interests | — | — | — | 7.9−57.5%191% | 19+82.4%1707% | 10+14.6%536% | 8.9—— | |
| Net income attributable to shareholders | −13—— | −8.2—−165% | −7.7—−167% | −7.9—−192% | −19—−1707% | −10—−536% | −8.9—— | |
| Earnings per share, basic | -3.12—— | -8.36—— | -20.14r-1.01—— | -3.25—— | -33.17—— | -37.96r-1.52—— | -1.71—— | |
| Earnings per share, diluted | -3.12—— | -8.36—— | -20.14r-1.01—— | -3.25—— | -33.17—— | -37.96r-1.52—— | -1.71—— | |
| Shares, weighted average (basic) | 4.2+327%— | 1.0r1.0+156%— | 0.4r7.6−84.4%— | 2.4+337%— | 0.6+109%— | 0.3—— | — | |
| Shares, weighted average (diluted) | 4.2+327%— | 1.0r1.0+156%— | 0.4r7.6−84.4%— | 2.4+337%— | 0.6+109%— | 0.3r6.7−94.9%— | 5.2—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 2.2−79.6%72.4% | 11r11+63.5%69.0% | 6.6−26.3%55.6% | 8.9+44.3%63.2% | 6.2−16.1%48.3% | 7.4+26.8%75.3% | 5.8—74.4% | |
| Short-term investments | 0.0−8.6%1.3% | 0.0+0.7%0.3% | 0.0−3.1%0.4% | 0.0−0.9%0.3% | 0.0−3.6%0.4% | 0.0+9.6%0.5% | 0.0—0.5% | |
| Receivables | — | 0.5+31.8%3.0% | 0.4+35.5%3.0% | 0.3+196%1.8% | 0.1+639%0.7% | 0.0−73.7%0.1% | 0.0—0.6% | |
| Inventory | — | 1.0−22.8%6.2% | 1.2−23.0%10.5% | 1.6−35.1%11.5% | 2.5—19.5% | — | — | |
| Other current assets | 0.2−24.5%8.0% | 0.3r0.3−33.1%2.1% | 0.5−4.1%4.0% | 0.5−37.5%3.5% | 0.8−16.7%6.2% | 1.0+128%9.8% | 0.4—5.4% | |
| Current assets | 2.7−79.2%88.3% | 13+48.1%82.6% | 8.7−23.3%73.5% | 11+18.1%80.3% | 9.6+14.6%75.1% | 8.4+32.7%85.7% | 6.3—80.9% | |
| Property, plant and equipment | 0.2−77.7%7.3% | 1.0−20.6%6.4% | 1.2+72.8%10.6% | 0.7−20.0%5.1% | 0.9+177%7.1% | 0.3−19.1%3.3% | 0.4—5.2% | |
| Other intangible assets | — | 1.6−9.1%10.4% | 1.8−8.4%15.1% | 1.9−7.7%13.8% | 2.1+98.6%16.5% | 1.1−2.3%10.9% | 1.1—13.9% | |
| Total assets | 3.0−80.6%100% | 16+31.8%100% | 12−16.2%100% | 14+10.3%100% | 13+30.7%100% | 9.8+25.4%100% | 7.8—100% | |
| Accounts payable | 0.9+234%30.6% | 0.3r0.4+578%1.8% | 0.0−92.5%0.3% | 0.5−53.3%3.9% | 1.2r2.4−45.4%9.1% | 2.1+32.8%21.8% | 1.6—20.6% | |
| Current liabilities | 2.0+6.3%64.5% | 1.8−6.7%11.8% | 2.0−1.4%16.7% | 2.0−39.7%14.2% | 3.3+49.8%26.0% | 2.2+32.2%22.6% | 1.7—21.5% | |
| Lease liabilities (non-current) | — | 0.3−52.6%2.0% | 0.6+3932%5.5% | 0.0−95.9%0.1% | 0.4+106%3.0% | 0.2−23.7%1.9% | 0.2—3.2% | |
| Total liabilities | 2.0−8.9%64.5% | 2.1−18.0%13.8% | 2.6+29.8%22.1% | 2.0−45.6%14.3% | 3.7+54.2%29.0% | 2.4+25.0%24.6% | 1.9—24.7% | |
| Retained earnings | −130—−4298% | −117—−752% | −109—−923% | −101—−719% | −93—−731% | −75—−765% | −65—−829% | |
| Shareholders' equity | 1.1−92.0%35.5% | 13+45.9%86.2% | 9.2−23.9%77.9% | 12+33.2%85.7% | 9.1+23.1%71.0% | 7.4+25.5%75.4% | 5.9—75.3% | |
| Total liabilities and equity | 3.0−80.6%100% | 16+31.8%100% | 12−16.2%100% | 14+10.3%100% | 13+30.7%100% | 9.8+25.4%100% | 7.8—100% | |
| Shares outstanding | 5.3+167%— | 2.0+349%— | 0.4r8.9−86.6%— | 3.3+412%— | 0.7+102%— | 0.3r8.1−93.8%— | 5.2—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 0.2−3.6%— | 0.2−3.1%4.3% | 0.2+8.6%4.8% | 0.2+8.9%4.9% | 0.2+53.6%17.0% | 0.1+7.5%6.3% | 0.1—— | |
| Share-based compensation | 0.1−10.4%— | 0.1−13.4%2.4% | 0.1−50.5%3.0% | 0.3r0.3−60.1%6.7% | 0.7+14.4%64.1% | 0.6−38.6%32.0% | 1.0—— | |
| Cash from operating activities | −8.6—— | −8.1r−7.8—−164% | −7.0—−152% | −7.3—−176% | −16—−1430% | −9.8—−514% | −7.4—— | |
| Capital expenditure | — | — | −0.0—−0.2% | −0.2—−3.9% | −0.0—−3.6% | −0.0—−0.1% | −0.0—— | |
| Acquisitions, net of cash acquired | — | — | — | −0.5—−12.1% | — | — | — | |
| Cash from investing activities | — | — | −0.0—−0.2% | −0.7—−16.0% | −0.7—−61.8% | −0.0−100%−0.1% | 3.8—— | |
| Debt repaid | — | — | — | — | −0.3—−26.7% | — | — | |
| Shares issued | — | — | — | 12−30.0%290% | 17+37.5%1574% | 12—655% | — | |
| Cash from financing activities | 0.1−99.2%— | 12+164%248% | 4.7−56.4%101% | 11−29.1%258% | 15+38.8%1383% | 11—570% | −0.0—— | |
| Exchange-rate effect on cash | — | — | — | — | — | 0.5—26.0% | −0.4—— | |
| Change in cash | — | — | −2.3−186%−50.9% | 2.7—66.1% | −1.2−176%−109% | 1.6—81.8% | −4.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q1 FY2027to Sep 30, 2026 | Q4 FY2026to Jun 30, 2026 | Q3 FY2026to Mar 31, 2026 | Q2 FY2026to Dec 31, 2025 | Q1 FY2026to Sep 30, 2025 | Q4 FY2025to Jun 30, 2025 | Q3 FY2025to Mar 31, 2025 | Q2 FY2025to Dec 31, 2024 | Q1 FY2025to Sep 30, 2024 | Q2 FY2024to Dec 31, 2023 | Q1 FY2024to Sep 30, 2023 | Q4 FY2023to Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | 0.8−26.2%100% | 1.1−11.4%100% | 1.3*—100% | 1.3—100% | 1.1−10.4%100% | 1.3+40.2%100% | 1.2—100% | 0.9—100% | 2.3*—100% | |
| Cost of revenue | — | — | — | — | 0.6−2.3%77.5% | 0.7−7.0%64.0% | 0.7*—55.8% | 1.1—86.1% | 0.7−29.0%58.5% | 0.8−12.4%61.0% | 0.9r0.7—73.9% | 0.9r0.8—97.6% | 1.3r1.0*—57.0% | |
| Gross profit | — | — | — | — | 0.2−60.0%22.5% | 0.4−18.3%36.0% | 0.6*—44.2% | 0.2—13.9% | 0.5+42.2%41.5% | 0.5+2223%39.0% | 0.3—26.1% | 0.0—2.4% | 1.6*—68.0% | |
| Research and development | 2.7+7.8%— | 0.2−64.2%— | 0.8*+39.6%— | 1.0+140%— | 0.6−29.6%76.9% | 0.6r0.6−17.8%51.4% | 0.6r0.1*—44.2% | 0.4r0.9—33.7% | 0.9r1.1+46.8%80.5% | 0.7r0.8−45.8%55.4% | 0.6—49.2% | 1.3—143% | 0.6*—27.0% | |
| General and administrative | 7.5+29.7%— | 1.8+45.6%— | 2.4*+87.2%— | 1.7+9.9%— | 1.6−5.7%198% | 1.2r1.5−17.0%111% | 1.3r2.3*—96.5% | 1.6r1.3—126% | 1.7r1.6+26.0%155% | 1.5r1.4+15.0%118% | 1.4—110% | 1.3—144% | 1.4*—61.0% | |
| Operating expenses | 12+39.7%— | 2.0+4.4%— | 4.9*+160%— | 2.8+36.3%— | 2.3−15.8%279% | 1.9r2.2−13.7%172% | 1.9r2.4*—143% | 2.1r2.3—165% | 2.7+37.9%244% | 2.2−17.3%176% | 2.0—159% | 2.7—299% | 2.1r2.1*—92.4% | |
| Operating income | — | — | — | — | — | — | — | — | — | — | — | −2.5—−281% | −0.3*—−14.6% | |
| Interest and finance income | 0.2−14.0%— | 0.0−84.7%— | 0.0*−43.8%— | 0.0+188%— | 0.1+144%9.1% | 0.1+64.2%8.4% | 0.1*—4.0% | 0.0—1.3% | 0.0−81.7%2.7% | 0.1−58.0%4.5% | 0.2—13.4% | 0.1—15.1% | 0.1*—6.4% | |
| Other non-operating income (expense) | — | — | — | — | — | — | — | — | — | — | — | 0.1—15.1% | — | |
| Income before tax | −12—— | −2.0—— | −4.8*—— | −2.8—— | −2.0—−247% | −1.8r−1.7—−163% | −1.8r−1.8*—−141% | −2.1r−2.1—−164% | −2.6—−232% | −1.7—−133% | −1.5—−119% | −2.5—−281% | −0.3*—−14.6% | |
| Income from continuing operations | — | −2.0—— | −4.8*—— | −2.8—— | — | −1.8—−163% | −1.8*—−141% | −2.1—−164% | — | — | — | — | — | |
| Income from discontinued operations | — | — | −1.0*−2252%— | −0.2—— | — | — | 0.0*—3.5% | −0.1—−4.3% | — | — | — | — | — | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | — | — | — | 0.3*—13.0% | |
| Net income attributable to shareholders | −13—— | −2.3—— | −5.8*—— | −3.0—— | −2.0—−247% | −1.7—−154% | −1.8*—−137% | −2.1—−168% | −2.6—−232% | −1.7—−133% | −1.5—−119% | −2.5—−281% | −0.3*—−14.6% | |
| Earnings per share, basic | — | -0.42—— | — | -0.73—— | -0.51—— | -0.44—— | — | -1.94—— | -3.64—— | -2.71—— | -3.71r-0.19—— | -15.24r-0.76—— | — | |
| Earnings per share, diluted | — | -0.42—— | — | -0.73—— | -0.51—— | -0.44—— | — | -1.94—— | -3.64—— | -2.71—— | -3.71r-0.19—— | -15.24r-0.76—— | — | |
| Shares, weighted average (basic) | 5.5+38.3%— | 5.5+38.3%— | — | 4.0+269%— | 4.0+460%— | 4.0+538%— | — | 1.1—— | 0.7+77.2%— | 0.6+273%— | 0.4r8.0—— | 0.2r3.3—— | — | |
| Shares, weighted average (diluted) | 5.5+38.3%— | 5.5+38.3%— | — | 4.0+269%— | 4.0+460%— | 4.0+538%— | — | 1.1—— | 0.7+77.2%— | 0.6+273%— | 0.4r8.0—— | 0.2r3.3—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 1.1—83.8% | 1.1−88.3%83.8% | 2.2−79.6%72.4% | 5.2+10.2%56.5% | 7.0+103%62.1% | 9.3+67.1%69.8% | 11r11—69.0% | 4.7—50.4% | 3.4−64.1%40.2% | 5.6−17.1%53.3% | 9.5—62.5% | 6.7—61.7% | 8.9—63.2% | |
| Short-term investments | 0.0—3.1% | 0.0−5.9%3.1% | 0.0−8.6%1.3% | 0.0+2.6%0.5% | 0.0+4.6%0.4% | 0.0−0.8%0.3% | 0.0—0.3% | 0.0—0.4% | 0.0−8.3%0.5% | 0.0+0.6%0.4% | 0.0—0.3% | 0.0—0.4% | 0.0—0.3% | |
| Receivables | — | — | — | — | 0.2−30.3%1.6% | 0.3+20.6%2.6% | 0.5—3.0% | 0.4—4.0% | 0.3−29.6%3.1% | 0.3+71.7%2.7% | 0.4—2.4% | 0.2—1.5% | 0.3—1.8% | |
| Inventory | — | — | — | — | 0.9−14.1%8.5% | 0.9−27.0%6.7% | 1.0—6.2% | 0.8—8.8% | 1.1+48.1%13.0% | 1.2+7.7%11.7% | 0.7—4.9% | 1.1—10.4% | 1.6—11.5% | |
| Other current assets | 0.1—7.6% | 0.1−48.0%7.6% | 0.2−24.5%8.0% | 0.6+21.5%6.8% | 0.7+2.5%5.9% | 0.2+28.8%1.4% | 0.3r0.3—2.1% | 0.5—5.5% | 0.6−42.1%7.6% | 0.1−30.8%1.4% | 1.1—7.3% | 0.2—2.0% | 0.5—3.5% | |
| Current assets | 1.3—96.8% | 1.3−88.3%96.8% | 2.7−79.2%88.3% | 6.9+7.5%75.4% | 8.8+60.7%78.5% | 11+48.4%80.8% | 13—82.6% | 6.4—69.1% | 5.5−53.7%64.3% | 7.3−12.2%69.6% | 12—77.4% | 8.3—76.0% | 11—80.3% | |
| Property, plant and equipment | — | — | 0.2−77.7%7.3% | 0.6−42.0%7.0% | 0.8−37.9%6.8% | 0.9−34.4%6.6% | 1.0—6.4% | 1.1—11.9% | 1.2−16.9%14.5% | 1.3+118%12.8% | 1.5—9.7% | 0.6—5.6% | 0.7—5.1% | |
| Other intangible assets | — | — | — | 1.5−9.8%16.4% | 1.5−9.6%13.7% | 1.6−9.3%11.8% | 1.6—10.4% | 1.7—17.9% | 1.7−8.7%20.0% | 1.7−8.6%16.6% | 1.9—12.2% | 1.9—17.5% | 1.9—13.8% | |
| Total assets | 1.3—100% | 1.3−90.2%100% | 3.0−80.6%100% | 9.1−1.6%100% | 11+31.6%100% | 13+27.7%100% | 16—100% | 9.3—100% | 8.5−44.3%100% | 10−4.1%100% | 15—100% | 11—100% | 14—100% | |
| Accounts payable | 1.7—128% | 1.7+353%128% | 0.9+234%30.6% | 0.2−59.8%2.5% | 0.2−71.0%1.5% | 0.4+18354%2.8% | 0.3r0.4—1.8% | 0.6—6.0% | 0.6+87.5%6.8% | 0.0−99.5%0.0% | 0.3—2.0% | 0.4—3.5% | 0.5—3.9% | |
| Current liabilities | — | — | 2.0+6.3%64.5% | 2.2+20.2%24.2% | 1.5−17.4%13.2% | 1.6+8.3%11.6% | 1.8—11.8% | 1.8—19.8% | 1.8+6.6%21.1% | 1.4+7.2%13.7% | 1.7—11.0% | 1.3—12.3% | 2.0—14.2% | |
| Lease liabilities (non-current) | — | — | — | 0.0−92.7%0.3% | 0.1−76.6%1.1% | 0.2−66.0%1.6% | 0.3—2.0% | 0.4—4.5% | 0.5−34.1%6.2% | 0.6—6.1% | 0.8—5.3% | — | 0.0—0.1% | |
| Total liabilities | 2.5—192% | 2.5+41.5%192% | 2.0−8.9%64.5% | 2.2−0.7%24.5% | 1.6−30.9%14.3% | 1.8−14.5%13.3% | 2.1—13.8% | 2.3—24.3% | 2.3−6.6%27.3% | 2.1+54.5%19.8% | 2.5—16.3% | 1.3—12.3% | 2.0—14.3% | |
| Retained earnings | −133—−10151% | −133—−10151% | −130—−4298% | −124—−1357% | −121—−1081% | −119—−890% | −117—−752% | −115—−1244% | −113—−1333% | −111—−1058% | −105—−691% | −104—−952% | −101—−719% | |
| Shareholders' equity | −1.2—−91.8% | −1.2−110%−91.8% | 1.1−92.0%35.5% | 6.9−1.8%75.5% | 9.6+55.1%85.7% | 12+38.1%86.7% | 13—86.2% | 7.0—75.7% | 6.2−51.6%72.7% | 8.4—80.2% | 13—83.7% | −9.6r9.6—−87.7% | 12—85.7% | |
| Total liabilities and equity | 1.3—100% | 1.3−90.2%100% | 3.0−80.6%100% | 9.1−1.6%100% | 11+31.6%100% | 13+27.7%100% | 16—100% | 9.3—100% | 8.5−44.3%100% | 10−4.1%100% | 15—100% | 11—100% | 14—100% | |
| Shares outstanding | 5.5—— | 5.5+111%— | 5.3+167%— | 3.3+175%— | 2.8+287%— | 2.6+290%— | 2.0—— | 1.2—— | 0.7−87.2%— | 0.7−80.0%— | 5.7—— | 3.3—— | 3.3—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.2−27.2%— | 0.0−99.7%— | 0.0*−8.3%— | 0.1+0.0%— | 0.1−0.0%6.5% | 0.1−2.5%4.7% | 0.1*—4.0% | 0.1r0.1—4.1% | 0.1−3.7%4.8% | 0.1−0.5%4.3% | 0.1—4.5% | 0.1—6.1% | 0.1*—2.3% | |
| Share-based compensation | 0.1−6.5%— | 0.0−19.0%— | 0.0*−15.4%— | 0.0−4.2%— | 0.0+10.4%3.1% | 0.0−30.2%1.8% | 0.0*—2.0% | 0.0—3.2% | 0.0+26.8%2.1% | 0.0+15.0%2.3% | 0.0—1.5% | 0.0—2.8% | 0.0*—1.8% | |
| Cash from operating activities | −7.9—— | −1.1—— | −3.0*—— | −1.7*—— | −2.1r−2.4*—−250% | −1.9r−1.6—−172% | −2.1r−1.8*—−162% | −1.7*—−132% | −2.5*—−225% | −1.8—−144% | −1.8*—−149% | −2.2—−241% | −0.7*—−28.5% | |
| Cash from investing activities | — | 0.0—— | — | — | — | — | — | — | — | — | — | — | −0.0*—−1.5% | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | 0.3−97.6%— | 0.0—— | −0.0*−100%— | 0.2*−92.1%— | 0*−100%0.0% | −0.1−116%−12.2% | 8.2*—627% | 2.9*—231% | 0.3*—30.5% | 0.8—66.3% | — | — | 0*—0.0% | |
| Change in cash | — | — | — | — | — | — | — | — | — | — | — | — | −0.7*—−29.9% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Inmed Pharmaceuticals Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Restructuring 1 · Change in control 2 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 6 · Unregistered share sale 2 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 1
| Filed | What happened | Filing |
|---|---|---|
| Change in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changedResults announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Change in controlDirectors and officersMaterial agreement | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Delisting notice | 8-K | |
| Restructuring | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2022 | $6 M | Private placement after listing | $2 to $10 million | 2 | equity, options | SEC |
| Jun 2022 | $5 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Oct 2021 | $4 M | Issued in a merger or acquisition | $2 to $10 million | 54 | equity | SEC |
| Jul 2021 | $12 M | No. 2 | $10 to $50 million | 1 | equity, options | SEC |
| Jan 2018 | $2 M | No. 1 | Under $2 million | 2 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Inmed Pharmaceuticals Inc. compares in Biotechnology
- Market cap$9 M · higher than 9% of 726
- Revenue growth7.4% · higher than 51% of 438
- Price / book8.2× · lower than 19% of 534
- FCF yield-91.0% · higher than 11% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Inmed Pharmaceuticals Inc.🇨🇦 | $9 M | — | — | +7.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending June-2026
- Balance sheet:
- As of June-2026
- Employees:
- As of September 1, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Inmed Pharmaceuticals Inc.? Verify and update this profile — free
Show Inmed Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.